Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Regulus ( (RGLS) ) has issued an update.
Regulus Therapeutics Inc. has been acquired by Novartis AG through a merger agreement executed on April 29, 2025. The acquisition was completed on June 25, 2025, with Regulus becoming an indirect wholly owned subsidiary of Novartis. This transaction involved a tender offer for all outstanding shares of Regulus, with shareholders receiving a cash payment and a contingent value right per share. The merger led to the delisting of Regulus shares from Nasdaq and amendments to the company’s certificate of incorporation and bylaws.
The most recent analyst rating on (RGLS) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Regulus stock, see the RGLS Stock Forecast page.
Spark’s Take on RGLS Stock
According to Spark, TipRanks’ AI Analyst, RGLS is a Neutral.
Regulus’ stock is primarily buoyed by a potential merger with Novartis and strong technical momentum, despite severe financial performance challenges. The company’s financial instability, with no revenue and ongoing cash flow issues, is a significant risk. The merger provides a potential upside, contingent on regulatory approvals, but the speculative nature of the stock appeals mainly to long-term biotech investors.
To see Spark’s full report on RGLS stock, click here.
More about Regulus
Average Trading Volume: 2,697,293
Technical Sentiment Signal: Buy
Current Market Cap: $563.6M
Find detailed analytics on RGLS stock on TipRanks’ Stock Analysis page.